AzmanL/E+ via Getty ImagesSummary A brief update from my last coverage (11th July): I gave Cellebrite (NASDAQ:CLBT) a buy rating as the business's strong competitive advantage, mission-critical function, and great execution convinced me that it can continue to grow at 20%. In this update, I am revising my rating from buy to hold because valuation has caught up, which makes the upside much less attractive today despite a better fundamental outlook. 2Q24 results perform even better than I expected. In the ...